# First in Human Study of YB1-X7 Injection

> **NCT06889675** · NA · NOT_YET_RECRUITING · sponsor: **Shanghai Salvectors Biotechnology LTD.** · enrollment: 36 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** YB1-X7 Injection (IT)
- **DRUG:** YB1-X7 Injection (IV)

## Key facts

- **NCT ID:** NCT06889675
- **Lead sponsor:** Shanghai Salvectors Biotechnology LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-03-15
- **Primary completion:** 2027-01-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06889675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06889675, "First in Human Study of YB1-X7 Injection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06889675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*